Analysis of the Response Time to Involved-field Radiotherapy in Primary Gastrointestinal Low-grade B-cell Lymphoma

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2020 Sep 2

PMID 32867796

Citations 4

Authors

Kyu Hye Choi

Han Hee Lee

Seung-Eun Jung

Kyung-Sin Park

Joo-Hyun O

Young-Woo Jeon

Byung-Ock Choi

Seok-Goo Cho

Affiliations

Soon will be listed here.

Abstract

Background: Early-stage primary gastrointestinal (GI) low-grade B-cell lymphoma shows good therapeutic response to primary radiotherapy. However, there is no clear guideline for the evaluation of response to radiation therapy currently. The aim of this study was to analyze the relationship between the best response time and the clinical course after radiotherapy.

Methods: Patients who underwent radiotherapy for treatment of primary GI low-grade B-cell lymphoma from September 2007 to December 2018 at Seoul St. Mary's Hospital were included. Early responders were defined by best response within 6 months after radiotherapy, and delayed responders after 6 months. Clinical and pathological factors associated with delayed response and survival analyses were performed to investigate the recurrence and survival during follow-up.

Results: A total of 43 patients were evaluated and the number of gastric mucosa-associated lymphoid tissue and duodenal follicular lymphoma was 36 and 7, respectively. All of 43 patients showed complete remission to radiotherapy and the best response time after radiotherapy was a median of 3 months. There were 8 delayed responders with a median duration of 8.9 months. Early and delayed responders were characterized by a significant difference in depth of invasion beyond the mucosal layer.

Conclusions: Delayed responders did not show differences in oncological outcomes compared with early responders. They were allowed to watch and wait for an additional 6 to 12 months without further treatment.

Citing Articles

Definitive Radiotherapy for Stage I Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Cohort of Unique-Dose Administration of 30 Gy in 15 Fractions and Analysis of Remission Duration.

Katano A, Yamashita H World J Oncol. 2024; 15(3):506-510.

PMID: 38751706 PMC: 11092405. DOI: 10.14740/wjon1846.

Deep learning model for predicting the survival of patients with primary gastrointestinal lymphoma based on the SEER database and a multicentre external validation cohort.

Wang F, Chen L, Liu L, Jia Y, Li W, Wang L J Cancer Res Clin Oncol. 2023; 149(13):12177-12189.

PMID: 37428248 DOI: 10.1007/s00432-023-05123-0.

Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience.

Min G, Kang D, Lee H, Kim S, Kim T, Jeon Y Ann Hematol. 2023; 102(4):877-888.

PMID: 36840791 PMC: 9998564. DOI: 10.1007/s00277-023-05130-8.

Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.

Hadi I, Schummer A, Dreyling M, Eze C, Bodensohn R, Roengvoraphoj O Sci Rep. 2021; 11(1):22586.

PMID: 34799601 PMC: 8604980. DOI: 10.1038/s41598-021-01851-w.

References

Goda J, Gospodarowicz M, Pintilie M, Wells W, Hodgson D, Sun A . Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010; 116(16):3815-24. DOI: 10.1002/cncr.25226. View

Yahalom J, Illidge T, Specht L, Hoppe R, Li Y, Tsang R . Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015; 92(1):11-31. DOI: 10.1016/j.ijrobp.2015.01.009. View

Vetro C, Romano A, Chiarenza A, Conticello C, Donnarumma D, Gorgone A . Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up. Hematol Oncol. 2011; 30(4):180-5. DOI: 10.1002/hon.1022. View

Ruskone-Fourmestraux A, Lavergne A, Aegerter P, Megraud F, Palazzo L, de Mascarel A . Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001; 48(3):297-303. PMC: 1760135. DOI: 10.1136/gut.48.3.297. View

Brady J, Binkley M, Hajj C, Chelius M, Chau K, Balogh A . Definitive radiotherapy for localized follicular lymphoma staged by F-FDG PET-CT: a collaborative study by ILROG. Blood. 2018; 133(3):237-245. DOI: 10.1182/blood-2018-04-843540. View

Hussell T, Isaacson P, Crabtree J, Spencer J . The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993; 342(8871):571-4. DOI: 10.1016/0140-6736(93)91408-e. View

Juarez-Salcedo L, Sokol L, Chavez J, Dalia S . Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. Cancer Control. 2018; 25(1):1073274818778256. PMC: 6028178. DOI: 10.1177/1073274818778256. View

Nakamura S, Matsumoto T . Gastrointestinal lymphoma: recent advances in diagnosis and treatment. Digestion. 2013; 87(3):182-8. DOI: 10.1159/000350051. View

Lee H, Oh D, Yang K, Ko Y, Ahn Y, Kim W . Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma. Cancer Res Treat. 2018; 51(2):547-555. PMC: 6473297. DOI: 10.4143/crt.2018.190. View

10.

Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M . Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut. 2001; 48(4):454-60. PMC: 1728260. DOI: 10.1136/gut.48.4.454. View

11.

Gong E, Ahn J, Jung H, Park H, Ko Y, Na H . Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Gut Liver. 2016; 10(5):706-13. PMC: 5003192. DOI: 10.5009/gnl15510. View

12.

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

13.

Vrieling C, de Jong D, Boot H, de Boer J, Wegman F, Aleman B . Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008; 87(3):405-11. DOI: 10.1016/j.radonc.2008.02.012. View

14.

El-Zahabi L, Jamali F, El-Hajj I, Naja M, Salem Z, Shamseddine A . The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest Endosc. 2006; 65(1):89-96. DOI: 10.1016/j.gie.2006.05.009. View

15.

Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M . Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003; 97(10):2462-73. DOI: 10.1002/cncr.11415. View

16.

Kim S, Lim D, Ahn Y, Kim W, Kim S, Ko Y . Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2013; 19(36):6062-8. PMC: 3785628. DOI: 10.3748/wjg.v19.i36.6062. View

17.

Tsang R, Gospodarowicz M . Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol. 2005; 23(1):10-7. DOI: 10.1002/hon.743. View

18.

Haas R, Poortmans P, de Jong D, Aleman B, Dewit L, Verheij M . High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003; 21(13):2474-80. DOI: 10.1200/JCO.2003.09.542. View

19.

Ruskone-Fourmestraux A, Fischbach W, Aleman B, Boot H, Du M, Megraud F . EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011; 60(6):747-58. DOI: 10.1136/gut.2010.224949. View

20.

Koch P, del Valle F, Berdel W, Willich N, Reers B, Hiddemann W . Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001; 19(18):3874-83. DOI: 10.1200/JCO.2001.19.18.3874. View